Table 1 Concordance of result information between ClinicalTrials.gov and corresponding publications for phase III trials published in high-impact journals between January 1, 2016, and June 30, 2017
Result informationb,c | Trials reporting results in both sources, no. (%) | Result information in both sources | ||
|---|---|---|---|---|
Concordant, no. (%) | Discordant, no. (%) | Cannot be compared, no. (%) | ||
Cohort characteristics | ||||
Completion rate | 94 (100) | 69 (73) | 22 (23) | 3 (3) |
Age distribution | 93 (99) | 70 (75) | 20 (22) | 3 (3) |
Sex distribution | 89 (95) | 67 (75) | 19 (21) | 3 (3) |
Race/ethnicity distribution | 35 (37) | 23 (66) | 12 (34) | 0 |
Trial intervention | 94 (100) | 83 (88) | 11 (12) | 0 |
Primary efficacy endpointa | 94 (100) | 70 (74) | 20 (21) | 4 (4) |
Serious adverse events | 93 (99) | 41 (44) | 24 (26) | 28 (30) |